妊娠期阿昔洛韦、恩曲他滨、拉米夫定和二甲双胍母胎浓度的生理药代动力学模型预测
该研究利用Simcyp V20中的母胎生理药代动力学(PBPK)模型,完全自下而上预测妊娠期及分娩时阿昔洛韦、恩曲他滨、拉米夫定和二甲双胍的母胎暴露。模型预测的暴露与观察到的母体和脐带暴露匹配,药代动力学参数在观察值的两倍范围内。整合胎儿与母体系统参数及离体胎盘灌注数据,可扩展妊娠期PBPK模型的应用,并用于临床试验和母胎风险评估。
要点
- PBPK模型可预测妊娠期阿昔洛韦、恩曲他滨、拉米夫定和二甲双胍的母胎暴露。
- 预测的药代动力学参数在观察值的两倍范围内。
- 该模型可辅助临床试验设计和母胎风险评估。
核心结论
- 整合胎儿与母体系统参数及离体胎盘灌注实验数据,可促进和扩展妊娠期PBPK模型的应用。
- 此类模型可用于指导临床试验以及母亲用药或意外暴露于环境毒物后的母胎风险评估。
研究设计与样本
- 使用Simcyp Simulator V20中的详细母胎PBPK模型预测妊娠期和分娩时阿昔洛韦、恩曲他滨、拉米夫定和二甲双胍的母胎药物暴露。
- 动态模型包括母体、胎儿和胎盘生理参数的妊娠期变化,胎盘动力学使用已发表的四种化合物的离体数据参数化,并在有数据时纳入羊水数据。
- PBPK预测结果与观察数据采用两倍标准进行比较。
主要发现
- 母胎PBPK模型完全自下而上开发,未进行任何参数调整。
- 模型预测的暴露与观察到的母体和脐带暴露匹配:阿昔洛韦(6项母体研究,均报告脐带暴露)、恩曲他滨(6项母体研究,其中4项报告脐带暴露)、拉米夫定(5项母体研究,其中4项报告脐带暴露)和二甲双胍(7项研究,其中6项报告脐带暴露)。
- 预测的药代动力学参数在观察值的两倍范围内。
临床怎么用
- 可利用母胎PBPK模型预测妊娠期药物暴露,辅助临床试验设计和母胎风险评估。
- 在缺乏母胎暴露数据时,PBPK模型可提供预测信息,但需结合临床判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Concerns over maternal and fetal drug exposure during pregnancy highlight the need for improved understanding of drug distribution to the fetus through the placental barrier. OBJECTIVE: Our objective was to predict maternal and fetal drug disposition using a physiologically based pharmacokinetic (PBPK) modeling approach. METHODS: We used the detailed maternal-placental-fetal PBPK model within the Simcyp Simulator V20 to predict the maternal and fetal drug exposure of acyclovir, emtricitabine, lamivudine, and metformin during pregnancy and at delivery. The dynamic model includes gestational changes to the maternal, fetal, and placental physiological parameters. Placental kinetics were parameterized using published ex vivo data for these four compounds. Amniotic data were included where available. PBPK predictions were compared with the observed data using twofold criteria. RESULTS: Maternal-fetal PBPK models were developed completely from the bottom up without any parameter adjustments. The PBPK model-predicted exposures matched the observed maternal and umbilical exposure for acyclovir (six maternal studies, all of which all reported umbilical exposure), emtricitabine (six maternal studies, of which four reported umbilical exposure), lamivudine, (five maternal studies, of which four reported umbilical exposure), and metformin (seven studies, of which six reported umbilical exposure). Predicted pharmacokinetic parameters were within twofold of the observed values. CONCLUSION: Integration of fetal and maternal system parameters within PBPK models, together with experimental data from ex vivo placental perfusion studies, facilitated and extended the application of the pregnancy PBPK model. Such models can also be used inform clinical trials and maternal/fetal risk assessment following maternally administered drugs or unintended exposure to environmental toxicants.
引用
- Abduljalil K, Pansari A, Ning J, et al. Prediction of Maternal and Fetal Acyclovir, Emtricitabine, Lamivudine, and Metformin Concentrations during Pregnancy Using a Physiologically Based Pharmacokinetic Modeling Approach. Clin Pharmacokinet. 2022. PMID: 35067869. doi:10.1007/s40262-021-01103-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。